新闻
CMS: Approval Of Drug Clinical Trials For Ulcerative Colitis & Crohn's Disease Of Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001.
26 May 2026 10:55On 22 May 2026, the innovative drug CMS-D001 Tablets has been granted the Drug Clinical Trial Approval Notice by the National Medical Products Administration of the People's Republic of China...
Attachments:
Source: ShareInvestor Express
